

Aktuelle Publikationen von Mitarbeitern oder unter Beteiligung von Mitarbeitern der Klinik und Poliklinik für Psychiatrie und Psychotherapie im Jahr 2006

Articles, Editorial Material, Letters, News Items, Notes und Reviews

Amann-Zalcenstein D, Avidan N, Kanyas K, Ebstein RP, Kohn Y, Hamdan A, Ben-Asher E, Karni O, Mujaheed M, Segman RH, **Maier W**, Macciardi F, Beckmann JS, Lancet D, Lerer B. AHI1, a pivotal neurodevelopmental gene, and C6orf217 are associated with susceptibility to schizophrenia. *Eur J Hum Genet.* 2006;14(10): 1111-9 (Impact(2006)=3.697)

Backmund M, Meyer K, **Schütz C**, Reimer J. Factors associated with exposure to hepatitis B virus in injection drug users. *Drug Alcohol Depend.* 2006;84(2): 154-9 (Impact(2006)=3.213)

Bechdorf A, Ruhrmann S, **Wagner M**, **Maier W**, Klosterkötter J. Frühinterventionen vor schizophrenen Ersterkrankungen. *Nervenheilkunde.* 2006;25(1-2): 17-27 (Impact(2006)=0.396)

Bender S, Dittmann-Balcar A, Schall U, Wolstein J, Klimke A, Riedel M, Vorbach EU, **Kühn KU**, Lambert M, Dittmann RW, Naber D. Influence of atypical neuroleptics on executive functioning in patients with schizophrenia: a randomized, double-blind comparison of olanzapine vs. clozapine. *Int J Neuropsychopharmacol.* 2006;9(2): 135-45 (Impact(2006)=5.184)

Delorme R, Durand CM, Betancur C, **Wagner M**, Ruhrmann S, Grabe HJ, Nygren G, Gillberg C, Leboyer M, Bourgeron T, Courtet P, Jollant F, Buresi C, Aubry JM, Baud P, Bondolfi G, Bertschy G, Perroud N, Malafosse A. No human tryptophan hydroxylase-2 gene R441H mutation in a large cohort of psychiatric patients and control subjects. *Biol Psychiatry.* 2006;60(2): 202-3 (Impact(2006)=7.154)

Domschke K, Braun M, Ohrmann P, Suslow T, Kugel H, Bauer J, Hohoff C, Kersting A, Engelien A, Arolt V, Heindel W, Deckert J. Association of the functional -1019C/G 5-HT1A polymorphism with prefrontal cortex and amygdala activation measured with 3 T fMRI in panic disorder. *Int J Neuropsychopharmacol.* 2006;9(3): 349-55 (Impact(2006)=5.184)

Duarte CR, **Schütz B**, **Zimmer A**. Incongruent pattern of neurokinin B expression in rat and mouse brains. *Cell Tissue Res.* 2006;323(1): 43-51 (Impact(2006)=2.58)

Erk S, Abler B, **Walter H**. Cognitive modulation of emotion anticipation. *Eur J Neurosci.* 2006;24(4): 1227-36 (Impact(2006)=3.709)

Etain B, Mathieu F, Rietschel M, **Maier W**, Albus M, McKeon P, Roche S, Kealey C, Blackwood D, Muir W, Bellivier F, Henry C, Dina C, Gallina S, Gurling H, Malafosse A, Preisig M, Ferrero F, Cichon S, Schumacher J, Ohlraun S, Borrmann-Hassenbach M, Propping P, Abou Jamra R, Schulze TG, Marusic A, Dernovsek ZM, Giros B, Bourgeron T, Lemaingue A, Bacq D, Betard C, Charon C, Nöthen MM, Lathrop M, Leboyer M. Genome-wide scan for genes involved in bipolar affective disorder in 70 European families ascertained through a bipolar type I early-onset proband: supportive evidence for linkage at 3p14. *Mol Psychiatry.* 2006;11(7): 685-94 (Impact(2006)=11.804)

Ewers M, Teipel SJ, Dietrich O, Schönberg SO, **Jessen F**, **Heun R**, Scheltens P, van de Pol L, **Frey mann NR**, Moeller HJ, Hampel H. Multicenter assessment of reliability of cranial MRI. *Neurobiol Aging.* 2006;27(8): 1051-9 (Impact(2006)=5.599)

Falkai P, **Maier W**. Fortschritte in der neurobiologischen Erforschung der Schizophrenie: Perspektiven für neue Therapieansätze. *Nervenarzt.* 2006;77 Suppl 2: S65-S76 (Impact(2006)=0.711)

Freitag CM, **Domschke K**, Rothe C, Lee YJ, Hohoff C, Gutknecht L, Sand P, Fimmers R, Lesch KP, Deckert J. Interaction of serotonergic and noradrenergic gene variants in panic disorder. *Psychiatr Genet.* 2006;16(2): 59-65 (Impact(2006)=2.141)

Fritze J, Aldenhoff J, Bermann F, **Maier W**, Möller HJ. Antipsychotika bei Demenz. *Nervenarzt.* 2006;77(1): 110-3 (Impact(2006)=0.711)

Georgi A, Jamra RA, Schumacher J, Becker T, Schmael C, Deschner M, **Höfels S**, Wulff M, Schwarz M, Klopp N, Illig T, Propping P, Cichon S, Nöthen MM, Rietschel M, Schulze TG. No association between genetic variants at the GRIN1 gene and bipolar disorder in a German sample. *Psychiatr Genet.* 2006;16(5): 183-4 (Impact(2006)=2.141)

Grabe HJ, Ruhrmann S, Ettelt S, **Buhtz F, Hochrein A, Schulze-Rauschenbach S, Meyer K**, Kraft S, Reck C, Pukrop R, Freyberger HJ, Klosterkötter J, Falkai P, John U, **Maier W, Wagner M**. Familiality of obsessive-compulsive disorder in nonclinical and clinical subjects. *Am J Psychiatry.* 2006;163(11): 1986-92 (Impact(2006)=8.25)

Grabe HJ, Ruhrmann S, Ettelt S, Müller A, **Buhtz F, Hochrein A, Schulze-Rauschenbach S**, Meyer K, Kraft S, Reck C, Pukrop R, Klosterkötter J, Falkai P, **Maier W, Wagner M**, John U, Freyberger HJ. Alexithymia in obsessive-compulsive disorder - results from a family study. *Psychother Psychosom.* 2006;75(5): 312-8 (Impact(2006)=4.333)

Hawellek B. Der Selbstmord im literarischen Werk von Walker Percy. *Fortschr Neurol Psychiatr.* 2006;74(2): 101-6 (Impact(2006)=0.546)

Heneka MT, Ramanathan M, Jacobs AH, Dumitrescu-Ozimek L, **Bilkei-Gorzo A**, Debeir T, Sastre M, Galldiks N, **Zimmer A**, Hoehn M, Heiss WD, Klockgether T, Staufenbiel M. Locus ceruleus degeneration promotes Alzheimer pathogenesis in amyloid precursor protein 23 transgenic mice. *J Neurosci.* 2006;26(5): 1343-54 (Impact(2006)=7.453)

Heun R, Freymann K, Erb M, Leube DT, **Jessen F**, Kircher TT, Grodd W. Successful verbal retrieval in elderly subjects is related to concurrent hippocampal and posterior cingulate activation. *Dement Geriatr Cogn Disord.* 2006;22(2): 165-72 (Impact(2006)=2.511)

Heun R, Kölsch H, Jessen F. Risk factors and early signs of Alzheimer's disease in a family study sample. Risk of AD. *Eur Arch Psychiatry Clin Neurosci.* 2006;256(1): 28-36 (Impact(2006)=3.042)

Höfgen B, Decker M, Mohr P, Schramm AM, Rostom SA, El-Subbagh H, Schweikert PM, Rudolf DR, Kassack MU, Lehmann J. Dopamine/serotonin receptor ligands. 10: SAR Studies on azecine-type dopamine receptor ligands by functional screening at human cloned D1, D2L, and D5 receptors with a microplate reader based calcium assay lead to a novel potent D1/D5 selective antagonist. *J Med Chem.* 2006;49(2): 760-9 (Impact(2006)=5.115)

Holzapfel J, Heun R, Lütjohann D, **Jessen F, Maier W, Kölsch H**. PPARD haplotype influences cholesterol metabolism but is no risk factor of Alzheimer's disease. *Neurosci Lett.* 2006;408(1): 57-61 (Impact(2006)=2.092)

Hurlemann R. Noradrenergic control of emotion-induced amnesia and hypermnesia. *Rev Neurosci.* 2006;17(5): 525-32 (Impact(2006)=3.32)

Hurlemann R, Bauer A, Vogeley K, Falkai P, **Wagner M, Maier W**. Molekulare Grundlagen der Schizophrenie - Der 5-HT2A-Rezeptor. *Nervenheilkunde.* 2006;25(1-2): 28-31 (Impact(2006)=0.396)

Illes F, Bernhardt T, **Prell K**, Rietz C, Rudinger G, Frölich L, **Maier W, Rietschel M**. Einstellung zu genetischen Untersuchungen auf Alzheimer-Demenz. *Z Gerontol Geriatr.* 2006;39(3): 233-9 (Impact(2006)=0.514)

Ivo R, Schulze TG, Schumacher J, Kesper K, Müller DJ, Kremer I, Dobrusin M, Mujaheed M, Murad I, Blanaru M, Bannoura I, Reshef A, Bachner-Melman R, Ebstein RP, Propping P, Belmaker RH, **Maier W**, Rietschel M, Nöthen MM, Cichon S. No evidence for association between NOTCH4 and schizophrenia in a large family-based and case-control association analysis. *Psychiatr Genet.* 2006;16(5): 197-203 (Impact(2006)=2.141)

Jäger M, Riedel M, Bottlender R, von Wilmsdorf M, Wölwer W, Gaebel W, Möller HJ, **Maier W**. Medikamentöse Akutbehandlung schizophrener Ersterkrankungen. *Nervenheilkunde.* 2006;25(1-2): 32-6 (Impact(2006)=0.396)

Jessen F. Demenzen.
Der niedergelassene Arzt. 2006;55: 11

Jessen F. Früherkennung von Demenzen - Bildgebung auch schon im Stadium der subjektiven Gedächtnisstörungen auffällig.
Neuro-Psychiatrische Nachrichten. 2006;10(4-5): 14

Jessen F. Neue Befunde zur MR-Spektroskopie.
Neuro-Psychiatrische Nachrichten. 2006;10(4-5): 13

Jessen F, Feyen L, Freymann K, Tepest R, Maier W, Heun R, Schild HH, Scheef L. Volume reduction of the entorhinal cortex in subjective memory impairment.
Neurobiol Aging. 2006;27(12): 1751-6 (Impact(2006)=5.599)

Jessen F, Fröhlich L, Schmidtke K, Hüll M. Die Herausforderung wird nur im Netzwerk zu bewältigen sein.
Neurologie & Psychiatrie. 2006;Sonderheft 1: 30-2

Jessen F, Scherk H, Träber F, **Theyson S, Berning J, Tepest R**, Falkai P, Schild HH, **Maier W, Wagner M**, Block W. Proton magnetic resonance spectroscopy in subjects at risk for schizophrenia.
Schizophr Res. 2006;87(1-3): 81-8 (Impact(2006)=4.264)

Jessen F, Träber F, **Freymann K, Maier W**, Schild HH, Block W. Treatment monitoring and response prediction with proton MR spectroscopy in AD.
Neurology. 2006;67(3): 528-30 (Impact(2006)=5.69)

Joe AY, Tielmann T, Bucerius J, Reinhardt MJ, Palmedo H, **Maier W**, Biersack HJ, **Zobel A**. Response-dependent differences in regional cerebral blood flow changes with citalopram in treatment of major depression.
J Nucl Med. 2006;47(8): 1319-25 (Impact(2006)=4.986)

Jönsson EG, Cichon S, Schumacher J, Abou Jamra R, Schulze TG, Deschner M, Forslund K, Hall H, Propping P, Czerski PM, Dmitrak-Weglarz M, Kapelski P, Driessen M, **Maier W**, Hauser J, Rietschel M, Nöthen MM. Association study of a functional promoter polymorphism in the XBP1 gene and schizophrenia.
Am J Med Genet B Neuropsychiatr Genet. 2006;141(1): 71-5 (Impact(2006)=4.463)

Kölsch H, Lütjohann D, **Jessen F**, Urbach H, von Bergmann K, **Maier W**, **Heun R**. Polymorphism in neuropeptide Y influences CSF cholesterol levels but is no major risk factor of Alzheimer's disease.
J Neural Transm. 2006;113(2): 231-8 (Impact(2006)=2.938)

Kölsch H, Lütjohann D, **Jessen F**, Von Bergmann K, **Schmitz S**, Urbach H, **Maier W**, **Heun R**. Polymorphism in ABCA1 influences CSF 24S-hydroxycholesterol levels but is not a major risk factor of Alzheimer's disease.
Int J Mol Med. 2006;17(5): 791-4 (Impact(2006)=1.854)

Korostishevsky M, Kremer I, Kaganovich A, Cholostoy A, Murad I, Muhaheed M, Bannoura I, **Rietschel M**, Dobrusin M, Bening-Abu-Shach U, Belmaker RH, **Maier W**, Ebstein RP, Navon R. Transmission disequilibrium and haplotype analyses of the G72/G30 locus: Suggestive linkage to

schizophrenia in Palestinian Arabs living in the north of Israel.

Am J Med Genet B Neuropsychiatr Genet. 2006;141B(1): 91-5 (Impact(2006)=4.463)

Lauterbach E, Brunner J, **Hawellek B**, Lewitzka U, Ising M, Bondy B, **Rao ML**, **Frahner C**, Rujescu D, Müller-Oerlinghausen B, Schley J, Heuser I, **Maier W**, Hohagen F, Felber W, Bronisch T. Platelet 5-HT_{2A} receptor binding and tryptophan availability in depression are not associated with recent history of suicide attempts but with personality traits characteristic for suicidal behavior.

J Affect Disord. 2006;91(1): 57-62 (Impact(2006)=3.138)

Leygraf A, Hohoff C, Freitag C, Willis-Owen SA, Krakowitzky P, Fritze J, **Franke P**, Bandelow B, Fimmers R, Flint J, Deckert J. Rgs 2 gene polymorphisms as modulators of anxiety in humans?

J Neural Transm. 2006;113(12): 1921-5 (Impact(2006)=2.938)

Lieb K, **Schläpfer TE**. Deep-brain stimulation for Parkinson's disease.

N Engl J Med. 2006;355(21): 2256; author reply 2256 (Impact(2006)=51.296)

Linnebank M, Moskau S, Farmand S, Fliessbach K, **Kölsch H**, Bös M, Grothe C, Becker D, Harbrecht U, Pohl C, Wüllner U, Klockgether T. Homocysteine and carotid intima-media thickness in a German population: lack of clinical relevance.

Stroke. 2006;37(11): 2840-2 (Impact(2006)=5.391)

Maier W. Do schizoaffective disorders exist at all?

Acta Psychiatr Scand. 2006;113(5): 369-71 (Impact(2006)=3.857)

Maier W, Sass H. Zertifizierte Fortbildung in der Psychiatrie. Neue Entwicklungen in Pathogenese, Therapie und Versorgung der Schizophrenie.

Nervenarzt. 2006;77 Suppl 2: S61 (Impact(2006)=0.711)

Maier W, **Zobel A**, **Kühn KU**. Clinical impact of recently detected susceptibility genes for schizophrenia.

Dialogues Clin Neurosci. 2006;8(1): 79-84 (Impact(2006)=0)

Maier W, **Zobel A**, **Wagner M**. Schizophrenia and bipolar disorder: differences and overlaps.

Curr Opin Psychiatry. 2006;19(2): 165-70 (Impact(2006)=1.081)

Mendizábal V, **Zimmer A**, Maldonado R. Involvement of kappa/dynorphin system in WIN 55,212-2 self-administration in mice.

Neuropsychopharmacology. 2006;31(9): 1957-66 (Impact(2006)=5.889)

Mössner R, Freitag CM, Gutknecht L, Reif A, Tauber R, **Franke P**, Fritze J, Wagner G, Peikert G, Wenda B, Sand P, **Rietschel M**, Garritsen H, Jacob C, Lesch KP, Deckert J. The novel brain-specific tryptophan hydroxylase-2 gene in panic disorder.

J Psychopharmacol. 2006;20(4): 547-52 (Impact(2006)=3.255)

Netzer C, Todt U, Heinze A, Freudenberg J, Zumbroich V, Becker T, Goebel I, **Ohlraun S**, Goebel H, Kubisch C. Haplotype-based systematic association studies of ATP1A2 in migraine with aura.

Am J Med Genet B Neuropsychiatr Genet. 2006;141(3): 257-60 (Impact(2006)=4.463)

Ofek O, **Karsak M**, Leclerc N, Fogel M, Frenkel B, Wright K, Tam J, Attar-Namdar M, Kram V, Shohami E, Mechoulam R, **Zimmer A**, Bab I. Peripheral cannabinoid receptor, CB₂, regulates bone mass.

Proc Natl Acad Sci U S A. 2006;103(3): 696-701 (Impact(2006)=9.643)

Pitschel-Walz G, Bäuml J, Bender W, Engel RR, **Wagner M**, Kissling W. Psychoeducation and compliance in the treatment of schizophrenia: results of the Munich Psychosis Information Project Study.

J Clin Psychiatry. 2006;67(3): 443-52 (Impact(2006)=5.533)

Quednow BB, Jessen F, Kühn KU, Maier W, Daum I, Wagner M. Memory deficits in abstinent MDMA (ecstasy) users: neuropsychological evidence of frontal dysfunction.
J Psychopharmacol. 2006;20(3): 373-84 (Impact(2006)=3.255)

Quednow BB, Kühn KU, Beckmann K, Westheide J, Maier W, Wagner M. Attenuation of the prepulse inhibition of the acoustic startle response within and between sessions.
Biol Psychol. 2006;71(3): 256-63 (Impact(2006)=2.698)

Quednow BB, Wagner M, Westheide J, Beckmann K, Bliesener N, Maier W, Kühn KU. Sensorimotor gating and habituation of the startle response in schizophrenic patients randomly treated with amisulpride or olanzapine.
Biol Psychiatry. 2006;59(6): 536-45 (Impact(2006)=7.154)

Quednow BB, Westheide J, Kühn KU, Werner P, Maier W, Hawellek B, Wagner M. Normal prepulse inhibition and habituation of acoustic startle response in suicidal depressive patients without psychotic symptoms.
J Affect Disord. 2006;92(2-3): 299-303 (Impact(2006)=3.138)

Radetzki U, Leser U, **Schulze-Rauschenbach SC**, Zimmermann J, Lüssem J, Bode T, Cremers AB. Adapters, shims, and glue--service interoperability for in silico experiments.
Bioinformatics. 2006;22(9): 1137-43 (Impact(2006)=4.894)

Riemenschneider M, Konta L, Friedrich P, Schwarz S, Taddei K, Neff F, Padovani A, **Kölsch H**, Laws SM, Klopp N, Bickeböller H, Wagenpfeil S, Mueller JC, Rosenberger A, Diehl-Schmid J, Archetti S, Lautenschlager N, Borroni B, Müller U, Illig T, **Heun R**, Egensperger R, Schlegel J, Förstl H, Martins RN, Kurz A. A functional polymorphism within plasminogen activator urokinase (PLAU) is associated with Alzheimer's disease.
Hum Mol Genet. 2006;15(16): 2446-56 (Impact(2006)=8.099)

Schahab S, Heun R, Schmitz S, Maier W, Kölsch H. Association of polymorphism in the transcription factor LBP-1c/CP2/LSF gene with Alzheimer's disease and major depression.
Dement Geriatr Cogn Disord. 2006;22(1): 95-8 (Impact(2006)=2.511)

Schläpfer TE, Lancaster E, Heidbreder R, Strain EC, **Kosel M**, Fisch HU, Pearlson GD. Decreased frontal white-matter volume in chronic substance abuse.
Int J Neuropsychopharmacol. 2006;9(2): 147-53 (Impact(2006)=5.184)

Schmitt I, Wüllner U, Healy DG, Wood NW, **Kölsch H, Heun R.** The ADH1C stop mutation in multiple system atrophy patients and healthy probands in the United Kingdom and Germany.
Mov Disord. 2006;21(11): 2034 (Impact(2006)=3.323)

Schneider-Axmann T, Kamer T, **Moroni M**, Maric N, Tepest R, **Dani I**, Honer WG, Scherk H, **Rietschel M, Schulze TG**, Müller DJ, Cordes J, Schönell H, Steinmetz H, Gaebel W, Vogeley K, **Kühn KU, Wagner M, Maier W**, Träger F, Block W, Schild HH, Falkai P. Relation between cerebrospinal fluid, gray matter and white matter changes in families with schizophrenia.
J Psychiatr Res. 2006;40(7): 646-55 (Impact(2006)=3.7)

Schwab SG, Knapp M, Sklar P, Eckstein GN, **Sewekow C**, Borrmann-Hassenbach M, Albus M, Becker T, Hallmayer JF, Lerer B, **Maier W**, Wildenauer DB. Evidence for association of DNA sequence variants in the phosphatidylinositol-4-phosphate 5-kinase IIalpha gene (PIP5K2A) with schizophrenia.
Mol Psychiatry. 2006;11(9): 837-46 (Impact(2006)=11.804)

Skowronek MH, Georgi A, Jamra RA, Schumacher J, Becker T, Schmael C, Paul T, Deschner M, **Höfels S**, Wulff M, Schwarz M, Klopp N, Illig T, Propping P, Cichon S, Nöthen MM, Schulze TG, Rietschel M. No association between genetic variants at the ASCT1 gene and schizophrenia or bipolar disorder in a German sample.
Psychiatr Genet. 2006;16(6): 233-4 (Impact(2006)=2.141)

Tam J, Ofek O, Fride E, Ledent C, Gabet Y, Müller R, **Zimmer A**, Mackie K, Mechoulam R, Shohami E, Bab I. Involvement of neuronal cannabinoid receptor CB1 in regulation of bone mass and bone remodeling.

Mol Pharmacol. 2006;70(3): 786-92 (Impact(2006)=4.469)

Teipel S, Ewers M, Dietrich O, Schoenberg S, **Jessen F**, **Heun R**, **Freyman N**, Möller HJ, Hampel H. Multizentrische Reliabilität MRT-gestützter Volumetrie des Gehirns. Ergebnisse des Phantomtests und voxelbasierter Morphometrie im Kompetenznetz Demenzen.

Nervenarzt. 2006;77(9): 1086-92, 1094-5 (Impact(2006)=0.711)

Träber F, Block W, **Freyman N**, Gür O, Kucinski T, Hammen T, Ende G, Pilatus U, Hampel H, Schild HH, **Heun R**, **Jessen F**. A multicenter reproducibility study of single-voxel 1H-MRS of the medial temporal lobe.

Eur Radiol. 2006;16(5): 1096-103 (Impact(2006)=2.554)

von Trotha KT, **Heun R**, **Schmitz S**, **Lütjohann D**, **Maier W**, **Kölsch H**. Influence of lysosomal acid lipase polymorphisms on chromosome 10 on the risk of Alzheimer's disease and cholesterol metabolism.

Neurosci Lett. 2006;402(3): 262-6 (Impact(2006)=2.092)

Wagner M, Baving L, Berg P, Cohen R, Rockstroh B. An ERP investigation of semantic priming, repetition priming, and negative priming in schizophrenic patients.

J Psychophysiol. 2006;20(3): 195-211 (Impact(2006)=1.634)

Wagner M, Rihs TA, Mosimann UP, Fisch HU, **Schläpfer TE**. Repetitive transcranial magnetic stimulation of the dorsolateral prefrontal cortex affects divided attention immediately after cessation of stimulation.

J Psychiatr Res. 2006;40(4): 315-21 (Impact(2006)=3.7)

Wessling A, Wölwer W, Heres S, Mayenberger M, Rummel C, Sievers M, **Wagner M**, Klosterkötter J, Gaebel W. Telefon-Hotline als niederschwelliges Angebot für Fragen zur Schizophrenie.

Nervenarzt. 2006;77(9): 1105-6, 1108-10 (Impact(2006)=0.711)

Wölwer W, Baumann A, Bechdorf A, Buchkremer G, Häfner H, Janssen B, Klosterkötter J, **Maier W**, Möller HJ, Ruhrmann S, Gaebel W. The German Research Network on Schizophrenia--impact on the management of schizophrenia.

Dialogues Clin Neurosci. 2006;8(1): 115-21 (Impact(2006)=0)

Bücher und Buchbeiträge

Göthert M, Bönisch H, Schlicker E, **Maier W** (2006) Psychopharmaka - Pharmakotherapie psychischer Erkrankungen. In: Aktories K, Förstermann U, Hofmann FB, Starke K (Hrsg.) Repetitorium - Allgemeine und spezielle Pharmakologie und Toxikologie. Urban & Fischer, München (123-137).

Heuser I, **Maier W** (2006) Altersbedingte Leiden - kein Schicksal. In: Hohagen F, Nessler T (Hrsg.) Wenn Geist und Seele streiken. Handbuch psychische Gesundheit. Südwest, München (294-301).

Maier W (2006) Franz Josef Kallmann (1897-1965). In: Hippus H, Holdorff B, Schliack H (Hrsg.) Nervenärzte 2. Biographien. Thieme, Stuttgart (97-106).

Maier W, Möller H-J (2006) Methodologische Probleme von Meta- und Poolanalysen. In: Möller H-J, Müller WE, Schmauß M (Hrsg.) Innovation und Wandel der antidepressiven Therapie in Deutschland. Thieme, Stuttgart (81-86).

Schläpfer TE (2006) Deep Brain Stimulation for Depression. In: McGraw-Hill Yearbook of Science & Technology 2007. McGraw-Hill, New York.